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OBJECTIVE—Bile acids (BA) participate in the maintenance of
metabolic homeostasis acting through different signaling path-
ways. The nuclear BA receptor farnesoid X receptor (FXR)
regulates pathways in BA, lipid, glucose, and energy metabolism,
which become dysregulated in obesity. However, the role of FXR
in obesity and associated complications, such as dyslipidemia
and insulin resistance, has not been directly assessed.
RESEARCH DESIGN AND METHODS—Here, we evaluate the
consequences of FXR deﬁciency on body weight development,
lipid metabolism, and insulin resistance in murine models of
genetic and diet-induced obesity.
RESULTS—FXR deﬁciency attenuated body weight gain and
reduced adipose tissue mass in both models. Surprisingly, glu-
cose homeostasis improved as a result of an enhanced glucose
clearance and adipose tissue insulin sensitivity. In contrast, hepatic
insulin sensitivity did not change, and liver steatosis aggravated
as a result of the repression of b-oxidation genes. In agreement,
liver-speciﬁc FXR deﬁciency did not protect from diet-induced
obesity and insulin resistance, indicating a role for nonhepatic
FXR in the control of glucose homeostasis in obesity. Decreasing
elevated plasma BA concentrations in obese FXR-deﬁcient mice
by administration of the BA sequestrant colesevelam improved
glucose homeostasis in a FXR-dependent manner, indicating that
the observed improvements by FXR deﬁciency are not a result of
indirect effects of altered BA metabolism.
CONCLUSIONS—Overall, FXR deﬁciency in obesity beneﬁ-
cially affects body weight development and glucose homeostasis.
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O
besity is characterized by an excess of adipose
tissue mass, which predisposes to metabolic
perturbations, including insulin resistance, hy-
perlipidemia, and fatty liver, promoting the de-
velopment of type 2 diabetes and cardiovascular disease.
Dysregulation of various metabolic pathways in tissues
such as adipose tissue, skeletal muscle, pancreas, and liver
lies at the basis of these metabolic complications, but the
exact mechanisms are still not well understood (1).
Nuclear receptors are ligand-activated transcription fac-
tors, which regulate gene expression by binding to speciﬁc
response elements in the promoters of target genes. The
farnesoid X receptor (FXR) is a key regulator of bile acid
(BA) metabolism. By promoting BA efﬂux from the liver,
inhibiting hepatic BA synthesis and intestinal absorption,
FXR controls the enterohepatic cycling of BA (2). Addi-
tionally, FXR regulates lipid metabolism, insulin sensi-
tivity, and energy homeostasis (3). FXR activation lowers
plasma and liver triglycerides by repressing sterol regula-
tory element–binding protein (SREBP)1c-mediated hepatic
lipogenesis (4) and by enhancing plasma triglyceride clear-
ance via apolipoprotein (apo)CII induction (5) and apoCIII
inhibition (6) in the liver, resulting in an increased lipo-
protein lipase (LPL) activity. Consequently, FXR-deﬁcient
(FXR
2/2) mice are dyslipidemic, displaying elevated plasma
triglycerides and total and HDL cholesterol (7–9).
The characterization of FXR
2/2 mice further revealed
an important function of FXR in the control of glucose
homeostasis. FXR
2/2 mice are transiently hypoglycemic
when fasted (8,10) and exhibit a delayed intestinal glucose
absorption (10) and a reduced hepatic glycogen content
(10–12). Hepatic gluconeogenic gene expression is de-
creased in the absence of FXR (11–13) and induced upon
FXR activation in vivo (14). Moreover, FXR
2/2 mice dis-
play peripheral insulin resistance with an impaired insulin
signaling response in adipose tissue and skeletal muscle
(8,13). Additionally, FXR may control adipose tissue biology.
FXR
2/2 mice exhibit a decrease in adipose tissue mass with
smaller adipocytes (8). Conversely, FXR activation in vitro
stimulates adipocyte differentiation (15) by promoting per-
oxisome proliferator–activated receptor (PPAR)-g activity
and inhibiting the Wnt/b-catenin pathway (16).
BA act as regulators of metabolic homeostasis also
through FXR-independent pathways (17). Apart from FXR,
BA have been reported to activate the G protein–coupled
BA receptor (TGR5), the pregnane X receptor (PXR), the
vitamin D receptor (VDR), or the formyl peptide receptor
(FPR) (17). TGR5 activation by BA increases energy ex-
penditure in thermogenic tissues by inducing deiodinase 2
(D2) (18) and improves glucose homeostasis by stimulat-
ing glucagon-like peptide 1 (GLP-1) secretion from intes-
tinal L cells (19,20). Hence, because FXR controls plasma
BA concentrations, the metabolic actions of FXR can be a
result of direct FXR-mediated and/or indirect BA-mediated
effects (2). BA metabolism can be pharmacologically
modulated by BA sequestrants (BAS), such as colesevelam,
which bind BA in the intestinal lumen and interrupt their
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ORIGINAL ARTICLEenterohepatic cycling. BAS lower plasma cholesterol
levels by stimulating hepatic BA synthesis from choles-
terol and increasing LDL receptor activity (3). In diabetic
patients, BAS improve glycemic control (21), associated
with an activation of the incretin system as a result of an
enhanced GLP-1 secretion as shown in rodent models of
diabetes (22,23).
Studies on the metabolic function of FXR have so far
been limited to lean FXR
2/2 mice. However, the role of
FXR in the adaptation to obesity and its metabolic com-
plications has not yet been assessed. To address this issue,
we investigated the impact of FXR deﬁciency in murine
models of genetic (ob/ob) and diet-induced obesity. Our
results show that FXR deﬁciency protects from excessive
body weight gain in both models by reducing adipose tis-
sue mass. Interestingly, hyperglycemia and glucose tol-
erance improved, associated with improved peripheral
glucose clearance and adipose tissue insulin sensitivity.
Liver insulin sensitivity was not altered by FXR deﬁci-
ency, and hepatic steatosis became even more pronounced,
associated with elevated plasma triglyceride levels and
reduced expression of genes implicated in b-oxidation.
Furthermore, liver-speciﬁcF X R - d e ﬁcient mice were not
protected from diet-induced obesity and insulin resistance,
indicating a role for nonhepatic FXR in the improvement
of glucose metabolism. Finally, to assess the contribution
of elevated plasma BA concentrations observed in FXR-
deﬁcient models of obesity, plasma BA levels were reduced
by administration of the BAS colesevelam. Colesevelam
treatment improved glucose homeostasis in genetic obesity
only in the presence of FXR, indicating that the changes in
BA concentrations are not responsible for the improved
glucose homeostasis in obese FXR
2/2 mice. Thus, selective
FXR antagonism or elimination of ligands, e.g., by BAS, may
be an interesting pharmacological option for the therapy of
metabolic disorders associated with obesity.
RESEARCH DESIGN AND METHODS
Animals. All experiments were performed with the approval of the Institut
PasteurdeLillereviewboard.Animalswerehousedina12-hlight/12-hdarkcycle
and maintained on standard chow (A0; SAFE). Unless stated otherwise, male
mice were used for experimentation. FXR
2/2 (7) and FXR-ﬂoxed mice (7) were
backcrossed for 7 or 10 generations, respectively, onto a C57Bl/6 J background.
FXR
+/+ob/ob and FXR
2/2ob/ob mice and lean littermates were generated by
crossing FXR
2/2 and leptin-deﬁcient mice (B6.V-Lep
ob/J; Charles River). Liver-
speciﬁcF X R
2/2 mice (FXR
ﬂox/ﬂoxAlb-Cre
+/2=LFXR
2/2) and wild-type litter-
mates (FXR
ﬂox/ﬂoxAlb-Cre
2/2=LFXR
+/+) were generated by crossing FXR-ﬂoxed
and Albumin-Cre recombinase expressing mice (C57BL/6-Tg[Alb-cre]21Mgn/J;
Charles River). To study diet-induced obesity, mice received a high-fat diet
(HFD; D12492; Research Diets; 60% kcal fat) and controls received a low-fat diet
(D12450B; Research Diets; 10% kcal fat), 20-week-old FXR
+/+ and FXR
2/2 mice
for 20 weeks and 10-week-old LFXR
2/2 and LFXR
+/+ mice for 9 weeks. The BAS
colesevelam (Daiichi Sankyo) was administered with the diet (2% in standard
chow) ad libitum to 10-week-old FXR
+/+ob/ob and FXR
2/2ob/ob mice for
3 weeks. Body weight was monitored weekly. Fat and lean mass were de-
termined by dual-energy X-ray absorptiometry (Piximus; GE Medical Systems
LUNAR). Food intake was estimated during six periods of 2 days. Animals were
killed after a 6-h fast by cervical dislocation. Tissues were removed and snap-
frozen in liquid nitrogen.
Plasma parameters. Blood was sampled after a 6-h fast, and parameters were
determinedas follows: bloodglucose (Accu-Check; RocheDiagnostics),insulin
(Mercodia), nonesteriﬁed free fatty acids (FFA; Wako), triglycerides (Bio-
merieux), leptin (R&D Systems), and total BA, as described (24). Lipoprotein
proﬁles in plasma pools were generated by fast protein liquid chromatography
(Superose 6 HR 10/30; Amersham GE Healthcare) with subsequent deter-
mination of triglycerides.
Indirect calorimetry. Mice were housed individually in metabolic cages
(Oxylet; PanLab) for 48 h to measure O2 consumption (Vo2)a n dC O 2 production
(VCO2). Energy expenditure was calculated as described (25).
VLDLproduction.Micewere intravenously injected with 500mg/kgTyloxapol
(Sigma) after a 6-h fast, and triglycerides were measured in plasma sampled as
indicated.
Assessment of glucose metabolism. For tolerance tests, 1 g/kg glucose or
2 IU/kg insulin (Actrapid Penﬁll; Novo Nordisk), respectively, was injected
intraperitoneally and blood glucose was measured as indicated. The metabolic
clearance rate (MCR) was determined by stable isotope dilution as described
(26). To measure the insulin signaling response, tissues were harvested 10 min
after intraperitoneal injection of 1 IU/kg insulin (Actrapid Penﬁll; Novo Nordisk)
or 0.9% NaCl into overnight-fasted female mice. Serine473-phosphorylated Akt
and total Akt protein expression (Cell Signaling Technology) were detected by
Western blot, and signals were quantiﬁed by GeneTool software (Syngene).
Pancreas morphometry was analyzed as described (27).
Quantitative RT-PCR. Total RNA was isolated from tissues by guanidinium
thiocyanate/phenol/chloroform extraction (28) and reverse transcribed into
cDNA (Superscript II kit; Applied Bioscience). Quantitative PCR (QPCR) was
performed with the BrilliantII SYBR Green QPCR Master Mix (Agilent) and
speciﬁc primers (Supplementary Table 1) on an mx3005 (Agilent). Gene expres-
sion was normalized to 28S, and the value in FXR
+/+ob/ob samples was set to 1.
Lipidomics. Lipidomics analysis of adipose tissue was performed as described
(29).
Statistical analysis. All values are reported as means 6 SEM. Statistical
signiﬁcance was analyzed as indicated by two-way ANOVA and Bonferroni
post hoc test or Mann-Whitney test using Prism (GraphPad). Differences were
considered signiﬁcant when P , 0.05. Partial least squares discriminant
analysis (PLS/DA) was performed using Matlab, version 7.5 (Mathworks) and
PLS Toolbox, version 4.2 (Eigenvector Research).
RESULTS
FXR deﬁciency attenuates weight gain in genetic
obesity. As a ﬁrst approach to assess the role of FXR in
obesity, FXR
2/2 mice were crossed into the ob/ob back-
ground to produce FXR
2/2ob/ob mice, which were com-
pared with FXR
+/+ob/ob controls.
The weight gain observed in FXR
+/+ob/ob mice was sig-
niﬁcantly attenuated by FXR deﬁciency, already from 7
weeks of age onward (Fig. 1A)( P , 0.0001; two-way
ANOVA). Dual-energy X-ray absorptiometry revealed a de-
crease in fat (22%) and less pronounced in lean (10%) mass
of FXR
2/2ob/ob mice (Fig. 1B). Concordantly, the esti-
mated food intake tended to decrease in FXR
2/2ob/ob
mice (15.5 6 1.1 vs. 18.9 6 0.8 kcal/day/mouse). Indirect
calorimetry demonstrated that Vo2 and VCO2 were equally
reduced in FXR
2/2ob/ob mice compared with FXR
+/+ob/ob
controls (Fig. 1C and D), resulting in nearly identical values
for the respiratory quotient (data not shown). Consistent
with the decrease in Vo2 and body weight, calculated energy
expenditure was lower in FXR
2/2ob/ob than in FXR
+/+ob/ob
mice (7.1 6 0.3 vs. 8.7 6 0.7 kcal/day/mouse) even though
the difference did not reach statistical signiﬁcance.
Overall, FXR deﬁciency leads to a decreased storage of
energy in the form of adipose tissue, resulting in a lower
total body weight.
FXR deﬁciency improves glucose homeostasis in
genetic obesity by increasing peripheral glucose
disposal. Because lean FXR
2/2 mice develop peripheral
insulin resistance (8,13), it was next assessed whether
FXR deﬁciency in obesity affects glucose homeostasis. In
contrast with hyperglycemic FXR
+/+ob/ob mice, FXR
2/2
ob/ob mice displayed normal blood glucose levels (Fig. 2A)
(P , 0.0001; two-way ANOVA). In addition, the hyper-
insulinemia typically observed in FXR
+/+ob/ob mice was
signiﬁcantly reduced in the absence of FXR (Fig. 2B). Con-
cordant with the decreased hyperglycemia and hyper-
insulinemia, glucose tolerance was signiﬁcantly improved
in FXR
2/2ob/ob mice (Fig. 2C), as a result of a combination
of lower fasting glycemia and improved glucose handling as
evident from the signiﬁcantly smaller integrated area under
the curve (iAUC) (Fig. 2D). The MCR of glucose was further
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2/2ob/ob mice (Fig. 2E), in-
dicative of a higher glucose disposal in the periphery. In
line, an insulin tolerance test showed that FXR
2/2ob/ob
mice are more insulin sensitive than FXR
+/+ob/ob mice
(Fig. 2F and G) with a more drastic decline of blood
glucose levels in response to the administered insulin
bolus (P , 0.0001; two-way ANOVA). Insulin-resistant
FXR
+/+ob/ob mice exhibited enlarged islets of Langerhans
(Fig. 2H, compare arrows) because of compensatory hy-
pertrophy. In contrast, islets of FXR
2/2ob/ob mice were
signiﬁcantly smaller (Fig. 2I), likely reﬂecting the relieved
metabolic pressure as a result of the improved insulin
sensitivity. These ﬁndings indicate that, in contrast with
lean mice, FXR deﬁciency might improve glucose homeo-
stasis in genetic obesity.
Adipose tissue, but not hepatic insulin sensitivity, is
improved in FXR
2/2ob/ob mice. To analyze the contri-
bution of peripheral tissues and the liver to the improve-
ment of insulin sensitivity, the phosphorylation of Akt,
a key mediator of the metabolic action of insulin, was
measured in response to an in vivo–administered insulin
bolus (Fig. 3A). Akt phosphorylation was increased in adi-
pose tissue of FXR
2/2ob/ob compared with FXR
+/+ob/ob
mice (2.83 vs. 1.53). In contrast, the response in skeletal
muscle (4.53 vs. 4.83) and liver (2.03 vs. 1.73) was not
different between genotypes.
Hepatic insulin resistance is often associated with a fatty
liver (30). Because FXR regulates lipogenesis in lean mice
(2), hepatic gene expression and lipid content were de-
termined. No changes were seen in the mRNA expression
of the key regulator of lipogenesis, SREBP1c (Fig. 3B).
Expression of genes involved in FA synthesis was only
modestly induced (acethyl CoA carboxylase [ACC]1, fatty
acid synthase [FAS], stearoyl CoA desaturase [SCD]1)i n
livers of FXR
2/2ob/ob mice (Fig. 3B). Nevertheless, the
hepatic triglyceride content was doubled in the absence of
FXR (Fig. 3C). The expression of PPAR-a, a key regulator of
FA oxidation, and carnitine palmitoyltransferase (CPT)1A,
which ensures the FA entry into the mitochondria, was
signiﬁcantly decreased in FXR
2/2ob/ob compared with
FXR
+/+ob/ob mice (Fig. 3B). Expression of ACC2,w h i c h
indirectly inhibits CPT1A,w a ss i g n i ﬁcantly higher, indicating
that a reduced FA oxidation likely contributes to the in-
creased steatosis in FXR
2/2ob/ob mice.
Thus, an improvement of adipose tissue insulin sensitivity
seems to account for the observed changes in glucose ho-
meostasis. Hepatic insulin sensitivity was not altered by
FXR deﬁciency, even though liver steatosis increased.
FXR
2/2ob/ob mice exhibit hypertriglyceridemia as
a result of an impaired intravascular triglyceride
clearance. Because FXR
2/2ob/ob mice display increased
liver steatosis and reduced adipose tissue mass, it was
tested whether this phenotype was associated with alter-
ations in triglyceride or FA metabolism. Plasma FFA con-
centrations were not different between genotypes (Fig. 4A).
In contrast, plasma triglyceride levels were strongly ele-
vated in FXR
2/2ob/ob compared with FXR
+/+ob/ob mice
(Fig. 4B). Analysis of the lipoprotein proﬁle revealed that
triglycerides were mainly increased in VLDL, but also
intermediate-density lipoprotein (IDL)/LDL-sized particles
(Fig. 4C). To determine whether this was because of al-
tered hepatic triglyceride secretion, plasma triglyceride
accumulation was assessed after inhibition of intravascular
lipolysis (Fig. 4D). Hepatic VLDL production was similar
between FXR
2/2ob/ob and FXR
+/+ob/ob mice, suggesting
that an impairment of intravascular triglyceride clearance
FIG. 1. FXR deﬁciency attenuates weight gain in ob/ob mice. A: FXR
+/+ob/ob (white bars and symbols) and FXR
2/2ob/ob mice (black bars and
symbols) (n = 9 to 10/group) were monitored weekly for body weight. Signiﬁcance of the overall effect of genotype (P < 0.0001) and age (P <
0.0001) as well as their interaction (P < 0.0001) was calculated by two-way ANOVA. B: Body composition was assessed by dual-energy X-ray
absorptiometry in 20-week-old mice (n = 9 to 10/group). Vo2 (C) and VCO2 (D) were determined in 20-week-old mice (n = 5/group) individually
housed in metabolic cages. Values are means 6 SEM. Differences between genotypes over time were analyzed by two-way ANOVA and Bonferroni
post hoc test; differences between genotypes were calculated by Mann-Whitney test (*P = 0.05, **P < 0.01, ***P < 0.001).
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sistently, hepatic mRNA levels of apoCII and apoAV,L P L
activators, were markedly repressed (by 65 and 74%, re-
spectively) in FXR
2/2ob/ob mice (Fig. 4E).
Hence, the repression of plasma triglyceride clearance
regulators combined with the reduction of adipose tis-
sue mass might result in the development of hyper-
triglyceridemia.
Total but not liver-speciﬁc FXR deﬁciency protects
from diet-induced obesity and insulin resistance. To
assess the impact of FXR deﬁciency in obesity in a model
expressing functional leptin, lean FXR
2/2 and FXR
+/+ mice
were fed a HFD for 20 weeks. Whereas FXR
+/+ mice rapidly
gained weight upon HFD feeding, body weight remained
signiﬁcantly lower in FXR
2/2 mice (Fig. 5A). Consistently,
plasma leptin levels were lower in FXR
2/2 mice (Fig. 5B).
Plasma triglycerides were signiﬁcantly higher in FXR
2/2
mice upon HFD feeding (Fig. 5C). FXR
2/2 mice further
displayed lower blood glucose (Fig. 5D) and plasma insulin
(Fig. 5E) concentrations and showed an improved glucose
tolerance (P , 0.0001; two-way ANOVA; Fig. 5F and G).
Hence, similar as in ob/ob mice, FXR deﬁciency protects
from diet-induced obesity and insulin resistance.
To determine the contribution of hepatic FXR to the
protection from diet-induced obesity and insulin resis-
tance, liver-speciﬁc FXR
2/2 mice (LFXR
2/2) and wild-type
littermates (LFXR
+/+) were fed a HFD for 9 weeks. Both
LFXR
2/2 and LFXR
+/+ mice developed obesity (Fig. 6A)a n d
displayed signiﬁcantly elevated plasma leptin levels upon
HFD feeding (Fig. 6B). LFXR
2/2 mice had signiﬁcantly
higher basal plasma triglycerides than LFXR
+/+ littermates
but were unaffected by HFD feeding (Fig. 6C). HFD-fed
FIG. 2. FXR deﬁciency improves glucose homeostasis in ob/ob mice. A: Fasting blood glucose was measured weekly in FXR
+/+ob/ob (white bars or
circles) and FXR
2/2ob/ob mice (black bars or circles) (n = 9 to 10/group). Signiﬁcance of the overall effect of the genotype (P < 0.0001) was
calculated by two-way ANOVA. B: Plasma insulin was determined in 12-week-old mice (n = 9 to 10/group). Blood glucose excursion (C) and in-
tegrated AUC (D) after administration of an intraperitoneal glucose bolus (1 g/kg glucose) were measured in 12-week-old mice (n = 9 to 10/group).
Signiﬁcance of the overall effect of genotype (P < 0.0001) and time (P < 0.0001) was calculated by two-way ANOVA. E: MCR was determined by
stable isotope dilution in 14-week-old mice (n = 5 to 6/group). Blood glucose excursion (F) and iAUC (G) after administration of an intraperitoneal
insulin bolus (2 IU insulin/kg) were measured in 13-week-old mice (n = 9 to 10/group). Signiﬁcance of the overall effect of genotype (P < 0.0001)
and time (P < 0.0001) was calculated by two-way ANOVA. H: Pancreata of 20-week-old mice (n = 9 to 10/group) were sectioned and submitted to
Papanicolaou staining. Arrows indicate islets of Langerhans (scale bar = 1 mm). I: Mean surface of the islets of Langerhans was quantiﬁed. Values
are means 6 SEM. Differences between genotypes over time were analyzed by two-way ANOVA and Bonferroni post hoc test; differences between
genotypes were calculated by Mann-Whitney test (*P = 0.05, **P < 0.01, ***P < 0.001). (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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2/2 and LFXR
+/+ mice became insulin resistant, dis-
playing hyperglycemia (P , 0.0001; two-way ANOVA)
(Fig. 6D) and elevated plasma insulin levels (Fig. 6E). In
addition, the diet-induced glucose intolerance was similar
in both genotypes (Fig. 6F and G). These ﬁndings indicate
that liver-speciﬁcF X Rd e ﬁciency does not protect from
diet-induced obesity and insulin resistance.
Modulation of BA metabolism by sequestration does
not affect glucose homeostasis in FXR
2/2ob/ob mice.
FXR deﬁciency led to elevated plasma BA concentrations
in genetic (394 6 86 mM vs. 44 6 13 mM; P , 0.001) and
diet-induced obesity (119 6 50 mM vs. 22 6 6 mM). Be-
cause BA exert regulatory functions independent of FXR
(17), we evaluated whether this increase may account
for the observed alteration of body weight and glucose
homeostasis.
The increased availability of plasma BA may lead to
the activation of the TGR5 signaling pathway sub-
sequently increasing energy expenditure in brown adi-
pose tissue (BAT) (18). However, the expression of the
TGR5 target genes UCP1 and D2 was decreased or un-
changed, respectively, in BAT of FXR
2/2ob/ob compared
with FXR
+/+ob/ob mice (Fig. 7A), indicating that TGR5
activity was not induced.
To assess whether reducing the elevated plasma BA levels
in FXR
2/2ob/ob mice would affect glucose homeostasis, the
BAS colesevelam was administered to FXR
2/2ob/ob and
FXR
+/+ob/ob mice for 3 weeks. Colesevelam successfully
reduced plasma BA concentrations in both genotypes by
80% already within 9 days of treatment (Fig. 7B). Body
weight slightly but signiﬁcantly increased with colesevelam
treatment only in FXR
2/2ob/ob mice (Fig. 7C). Colesevelam
decreased blood glucose levels in FXR
+/+ob/ob, but not
FXR
2/2ob/ob mice (Fig. 7D). The glucose intolerance
observed in untreated FXR+/+ob/ob mice improved upon
colesevelam treatment, whereas such effect was not ob-
served in FXR
2/2ob/ob mice (Fig. 7E and F). However,
both genotypes displayed increased plasma insulin con-
centrations upon treatment (Fig. 7G). Because BAS may
lower glycemia by activating the incretin system (23), the
expression of implicated intestinal genes was measured
(Supplementary Table 2). ProGIP, coding for GIP, ex-
pression was repressed by FXR deﬁciency, whereas
proglucagon, coding for GLP-1, was induced. Colesevelam
moderately induced PC1/3, the enzyme activating both
incretins, only in FXR
+/+ob/ob mice, unlikely explaining the
observed improvement of glucose homeostasis. Indeed,
plasma GLP-1 concentrations were not signiﬁcantly differ-
ent between genotypes and not enhanced by colesevelam
treatment (data not shown). Thus, reducing plasma BA
concentrations had no effect on glucose homeostasis in the
absence of FXR, suggesting that the alterations of glucose
metabolism observed in FXR deﬁciency are not mediated
by circulating BA.
FXR deﬁciency differentially affects the abundance
of long- and medium-chain triglyceride species in
adipose tissue of lean and ob/ob mice. FXR deﬁciency
improves glucose homeostasis in obesity, due at least in
FIG. 3. FXR deﬁciency improves adipose tissue, but not hepatic insulin sensitivity in ob/ob mice. A: Female FXR
+/+ob/ob (13-week-old; white bars)
and FXR
2/2ob/ob mice (black bars) (n = 4/group) were injected with either saline or insulin. Phosphorylation of Akt at Serine473 and total Akt
protein expression was determined by Western blot and the signal quantiﬁed. B: Gene expression was measured by QPCR. C: Triglyceride content
was determined enzymatically in livers of 20-week-old mice (n = 9 to 10/group). Values are means 6 SEM. Differences between genotypes were
calculated by Mann-Whitney test (*P < 0.05, **P < 0.01, ***P < 0.001). WAT, white adipose tissue; pAkt, Serine473-phosphorylated Akt; TG,
triglyceride.
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investigate changes in adipose tissue lipid composition
linked to FXR deﬁciency before the metabolic phenotype
fully develops, high-resolution lipidomics was performed
in subcutaneous adipose tissue from 6-week-old lean and
ob/ob FXR
2/2 and FXR
+/+ mice.
Overall, 133 lipid species were quantiﬁed. Total phos-
pholipid and sphingomyelin but not triglyceride content
was signiﬁcantly lower in obese than in lean mice
(Supplementary Fig. 1). These lipid classes were un-
affected by FXR deﬁciency. Of interest, a number of
triglyceride species was differentially affected by FXR
deﬁciency in lean and obese mice. Highly saturated
medium-chain triglycerides were signiﬁcantly higher in
obese than lean FXR
+/+ mice (Fig. 8A–C) and tended to
increase by FXR deﬁciency in both. In contrast, long-
chain, unsaturated triglycerides, signiﬁcantly elevated
by obesity in FXR
+/+ mice, increased in lean but de-
creased in obese mice by FXR deﬁciency (Fig. 8D–F).
Furthermore, long-chain triglycerides containing few
double-bounds, which were similar between lean and
obese FXR
+/+ mice, only decreased by FXR deﬁciency in
o b e s em i c e( F i g .8 G–I).
PLS/DA revealed that the global subcutaneous adipose
tissue lipid proﬁles clustered according to their genotype
(Fig. 8J). Lipid proﬁles are signiﬁcantly different between
lean and obese mice whether deﬁcient or not for FXR,
visualized as a clear separation by the latent variable (LV)1
plotted on the x-axis. Interestingly, an additional separa-
tion of lean FXR
+/+ and obese FXR
2/2 from lean FXR
2/2
and obese FXR
+/+ mice by LV2 indicates that FXR de-
ﬁciency modulates lipid proﬁles in an opposite manner in
the lean versus obese background.
DISCUSSION
The nuclear receptor FXR is a metabolic regulator that
controls BA and lipid as well as glucose and energy me-
tabolism (2). FXR can exert direct transcriptional control
or indirectly inﬂuence metabolic pathways by modulating
the homeostasis of BA, which control metabolism also
independent of FXR (17). The characteristics of FXR
2/2
mice, dyslipidemia (7–9), transient hypoglycemia upon
fasting (8,10), peripheral insulin resistance (8,13), and re-
duced adipose tissue mass (8,15), reﬂect the importance
of FXR for the maintenance of metabolic homeostasis. Yet,
the impact of FXR deﬁciency on obesity and associated
metabolic disorders has not been assessed. In the current
study we demonstrate that FXR deﬁciency in murine
models of genetic and diet-induced obesity attenuated
weight gain by reducing adipose tissue mass. FXR de-
ﬁciency further improved glucose homeostasis by enhanc-
ing peripheral glucose disposal and increasing adipose
tissue insulin sensitivity. This improvement is not medi-
ated by hepatic FXR, since liver insulin sensitivity was
unchanged and liver-speciﬁc FXR
2/2 mice were not pro-
tected from diet-induced obesity and insulin resistance.
The administration of the BAS colesevelam, which re-
duced the elevated plasma BA levels resulting from FXR
deﬁciency in obesity, further revealed that the improved
glucose homeostasis was independent of BA-mediated
pathways. FXR deﬁciency thus exerts a beneﬁcial effect
on body weight development and glucose homeostasis in
obesity.
FXR
2/2 mice display peripheral insulin resistance, but
reported results on the liver are contradicting (8,13,31).
Surprisingly, we observed an improvement of glucose ho-
meostasis by FXR deﬁciency in genetic and diet-induced
FIG. 4. FXR deﬁciency in ob/ob mice results in the accumulation of plasma triglycerides. A and B: Lipid parameters were measured in plasma of
12-week-old FXR
+/+ob/ob (white bars or circles) and FXR
2/2ob/ob mice (black bars or circles) (n = 9 to 10/group). C: Lipoprotein proﬁles were
determined in plasma pools of 13-week-old mice. D: VLDL production was assessed in 13-week-old female mice (n =8 –10/group) by measuring
plasma triglyceride concentrations subsequent to Tyloxapol injection. E: Gene expression was measured by QPCR in livers of 20-week-old mice
(n = 9 to 10/group). Values are means 6 SEM. Differences between genotypes were calculated by Mann-Whitney test (***P < 0.001). FFA, free
fatty acid; OD, optical density; TG, triglyceride.
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homeostasis in basal (lean) and challenged (obese) meta-
bolic conditions. The reduction of hyperglycemia in FXR
2/2
ob/ob mice resulted from an increased peripheral glucose
disposal associated with an improved adipose tissue in-
sulin sensitivity. This suggests that FXR in adipose tissue
contributes to the dysregulation of glucose metabolism in
obesity. Hypertrophic adipocytes develop insulin resis-
tance (32). Hence the reduced adipocyte size in FXR
2/2
ob/ob mice (16) might explain the increased insulin sensi-
tivity. In addition to adipose tissue, skeletal muscle is the
main peripheral tissue accounting for glucose uptake.
However, the insulin signaling response in skeletal muscle
was unaffected by FXR deﬁciency. Moreover, FXR is not
expressed in skeletal muscle (8) and muscle mass strongly
reduced in genetic obesity. We can therefore exclude the
involvement of skeletal muscle in the FXR deﬁciency–
mediated changes of glucose homeostasis.
FXR exerts a key function in the control of hepatic
glucose and lipid metabolism (2). In hepatic insulin re-
sistance, increased endogenous glucose production con-
tributes to hyperglycemia and continuous insulin-mediated
activation of lipogenesis leads to hyperlipidemia and may
cause a fatty liver (32). In contrast with adipose tissue,
FXR deﬁciency did not improve hepatic insulin sensitivity
in genetic obesity and liver-speciﬁc FXR deﬁciency did not
protect from diet-induced insulin resistance, a rather sur-
prising result regarding the importance of hepatic FXR for
the metabolic control of lean mice. Furthermore, hepatic
steatosis often associated with hepatic insulin resistance
increased in FXR
2/2ob/ob mice because of a repression
of b-oxidation. Moreover, the repression of hepatic LPL
cofactors led to an impaired intravascular triglyceride
clearance resulting in elevated plasma triglycerides. Over-
all, the changes in lipid metabolism appear to be primarily
a result of altered liver function, whereas the results on
insulin sensitivity emphasize a role for nonhepatic FXR in
the dysregulation of glucose homeostasis in obesity, most
probably in adipose tissue.
Several studies have shown that FXR controls adipocyte
differentiation and function (8,15,16). FXR expression oc-
curs early and transiently during adipocyte development,
inhibiting the Wnt/b-catenin pathway, thus allowing opti-
mal PPAR-g activation (16). Because the lack of hepatic
FXR does not seem to mediate the improvement of glucose
homeostasis in obesity, it would be of great interest to
study adipose tissue-speciﬁc FXR deﬁciency in obesity.
Unfortunately, in the currently available mouse models
Cre recombinase expression is driven by promoters from
late and/or nonspeciﬁc adipocyte genes (i.e., adiponectin
or aP2), rendering them inappropriate to study the in-
ﬂuence of genes acting earlier in the differentiation pro-
cess, such as FXR.
FXR deﬁciency in obesity was associated with elevated
plasma BA levels. BA have been reported to improve glu-
cose homeostasis independent of FXR by TGR5-mediated
stimulation of GLP-1 secretion (19,20). The administration
of the BAS colesevelam to ob/ob mice successfully re-
duced plasma BA concentrations but had no effect on glu-
cose homeostasis in the absence of FXR. Thus, elevated
FIG. 5. FXR deﬁciency protects from diet-induced obesity and insulin resistance. FXR
+/+ (white bars or circles) and FXR
2/2 mice (black bars or
circles) (n =7 –11/group) were fed a HFD for 20 weeks. A: Body weight was monitored weekly (n =7 –11/group). Signiﬁcance of the overall effect of
genotype (P < 0.0001) and age (P < 0.0001) as well as their interaction (P < 0.0001) was calculated by two-way ANOVA. Plasma leptin (B), plasma
triglyceride (TG) (C), blood glucose (D), and plasma insulin (E) were determined at the end of the feeding period (n =4 –9/group). Blood glucose
excursion (F) and integrated AUC (G) after administration of an intraperitoneal glucose bolus (1 g/kg glucose) were measured at the end of the
feeding period (n =6 –9/group). Signiﬁcance of the overall effect of genotype (P < 0.0001) and time (P < 0.0001) was calculated by two-way
ANOVA. Values are means 6 SEM. Differences between genotypes over time were analyzed by two-way ANOVA and Bonferroni post hoc test;
differences between genotypes were calculated by Mann-Whitney test (*P < 0.05, **P < 0.01, ***P < 0.001).
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served improvement in glucose homeostasis. BAS improve
glycemic control in type 2 diabetes, also partly via a TGR5-
mediated increase of GLP-1 (22,23). However, GLP-1 secre-
tion was unaffected by genotype or colesevelam treatment.
Thus, the observed FXR-dependent improvement of gly-
cemic control by colesevelam in ob/ob mice suggests that
FXR-mediated pathways contribute to the beneﬁcial effect
of BAS.
Contradictory to our observation that FXR deﬁciency is
beneﬁcial for glucose homeostasis in obesity, FXR acti-
vation has been shown to improve insulin resistance in
rodent models of diabetes (8,31,33). The reason for this
apparent inconsistency is currently unclear. However, the
pharmacological activation of a nuclear receptor does not
necessarily have opposite effects than the knockout of its
expression. The speciﬁc pharmacodynamics of the used
compounds may also affect FXR in a tissue-speciﬁc man-
ner (sBARM effect), whereas our study focused on whole-
body FXR deﬁciency.
Both genetic and diet-induced obesity are attenuated in
the absence of FXR. FXR deﬁciency leads to reduced ad-
ipose tissue mass (8,15,16) and adipocyte size (16) in lean
and ob/ob mice, limiting energy storage capacity. Because
food intake and energy expenditure only tended to de-
crease in FXR
2/2ob/ob mice, the decreased adipose tissue
mass most likely accounts for the reduced weight gain.
With regard to the moderate decrease in energy expendi-
ture, a central effect of FXR seems unlikely, additionally
since FXR expression in hypothalamus is only very weak
(34). Furthermore, the lack of TGR5 target gene induction
in BAT of FXR
2/2ob/ob mice argues against the implication
of a TGR5-cAMP-D2–mediated mechanism (18). If the re-
duced body weight was a direct effect of a decreased food
FIG. 6. Liver-speciﬁc FXR deﬁciency does not protect from diet-induced obesity and insulin resistance. LFXR
2/2 mice and LFXR
+/+ littermates (n =
7–12/group) were fed a HFD or a control diet (CD) for 10 weeks (LFXR
+/+, white bars and symbols; LFXR
2/2, black bars and symbols). A: Body
weight was monitored weekly. Signiﬁcance of the effect of diet (P < 0.0001) and age (P < 0.0001) as well as their interaction (P < 0.0001) was
calculated by two-way ANOVA. Plasma leptin (B) and plasma triglyceride (TG) (C) were determined at the end of the feeding period. D: Fasting
blood glucose was measured weekly. Signiﬁcance of the overall effect of diet (P < 0.0001) and age (P < 0.0001) as well as their interaction (P =
0.0217) was calculated by two-way ANOVA. E: Plasma insulin was measured after 6 weeks of feeding. Blood glucose excursion (F) and integrated
AUC (G) after administration of an intraperitoneal glucose bolus (1 g/kg glucose) were measured after 5 weeks of feeding (n = 6/group). Values are
means 6 SEM. Differences between diet groups over time were analyzed by two-way ANOVA and Bonferroni post hoc test; differences between
genotypes or diet groups were calculated by Mann-Whitney test. *Compares genotypes of the same diet group; $compares diet groups for LFXR
+/+;
§compares diet groups for LFXR
2/2 ($ or §P < 0.05; **, $$, or §§P < 0.01; $$$ or §§§P < 0.001).
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2/2ob/ob mice, the
hepatic triglyceride content would have also been reduced
and not elevated as observed.
Interestingly, the analysis of adipose tissue lipid proﬁles
by lipidomics revealed a differential alteration of certain
triglyceride classes in lean and obese mice by FXR de-
ﬁciency, e.g., long-chain, unsaturated triglycerides are
lowered by FXR deﬁciency in obese but increased in lean
mice. This observation demonstrates that FXR deﬁciency
speciﬁcally and opposingly affects adipose tissue metab-
olism as it does glucose homeostasis in lean and obese
conditions.
Overall, in contrast with lean mice, FXR deﬁciency in
obesity improves energy and glucose homeostasis. The se-
lective inhibition of FXR activity may thus be an appealing
option for the therapy of obesity and the related dysregu-
lation of glucose homeostasis.
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